Medical ozone therapy (O₃/O₂) involves the therapeutic administration of a precisely controlled mixture of ozone and oxygen gas. At physiological concentrations, ozone acts as a systemic oxidative preconditioning agent — triggering a controlled, hormetic oxidative stress response that activates the body's own antioxidant and immune defense systems. The mechanism is fundamentally different from high-dose oxidative damage: ozone at therapeutic doses stimulates the Nrf2/NF-κB pathway, upregulates antioxidant enzymes, modulates cytokines, activates immune cells, and improves tissue oxygenation. In cancer biology, this translates to immune activation, improved tumor microenvironment oxygenation, selective cytotoxicity in cancer cells with impaired antioxidant defenses, and meaningful reduction of chemotherapy and radiation-induced side effects. An honest assessment of the evidence: ozone has a compelling mechanistic rationale and strong preclinical data, a meaningful clinical evidence base for quality of life and supportive care outcomes, and a growing but still limited body of evidence for direct anti-tumor activity in humans. We use ozone therapy daily in the SEED Program for its systemic preconditioning, immune activation, and synergistic amplification of the other five core therapies — particularly IV Vitamin C, HBOT, and hyperthermia.
Medical ozone (O₃) is an unstable triatomic form of oxygen produced by passing pure medical-grade oxygen through a calibrated ozone generator. It is always administered as an O₃/O₂ mixture — never as pure ozone — at precisely controlled concentrations measured in micrograms per milliliter (μg/mL). The therapeutic window is well-defined: concentrations of 10–80 μg/mL (with an optimal range of 30–45 μg/mL per most protocols) produce the intended hormetic biological response. Below this range, therapeutic effect is minimal; above it, cytotoxic and inflammatory effects become clinically significant. Dose precision is not optional — it is the clinical practice standard that separates therapeutic ozone from harmful ozone exposure.
Ozone therapy has been practiced clinically in Europe — particularly Germany, Italy, Spain, and Cuba — for over a century. It is formally regulated in several European countries and has an extensive published evidence base in peer-reviewed journals, particularly in its applications for pain, circulatory disorders, infection, and oncology supportive care. In the United States, ozone therapy occupies a gray regulatory area: it is not FDA-approved as a drug or device, but it is practiced by licensed clinicians under state medical practice authority.
Routes of administration
Different administration routes produce different systemic and local effects. The primary routes used in integrative oncology are:
Major Autohemotherapy (MAH) — 50–200 mL of blood withdrawn, mixed with O₃/O₂ in a closed sterile system, and reinfused IV; the most widely studied systemic route with over 180 published clinical studies; produces the most potent and consistent systemic immune and oxidative preconditioning effects
Rectal Insufflation (RI) — O₃/O₂ gas administered directly into the colon via the rectum; rapidly absorbed through the colonic mucosa into systemic circulation; increasingly viewed as a systemic alternative to MAH; lower procedural burden; considered equivalent in many clinical protocols
Direct IV (DIV) — ozone gas administered directly intravenously in small volumes; less commonly used; higher risk profile than MAH or RI; not the preferred route for most clinical applications
Local / topical applications — ozonated oils, ozone water, insufflation of specific cavities; primarily for local tissue effects; outside the scope of SEED systemic therapy
Root Causes uses major autohemotherapy (MAH) as the primary systemic ozone delivery method in the SEED Program. MAH is the most thoroughly studied route for systemic effects, has the strongest published evidence base, and produces the most consistent immune activation and oxidative preconditioning response. It is administered daily during the 1-week SEED intensive as part of the core six protocol.
The central principle underlying ozone therapy's therapeutic effects is hormesis: the biological phenomenon in which a low-level stressor — in this case, a precisely controlled oxidative challenge — triggers an adaptive response that leaves the system more resilient than before. Ozone at therapeutic concentrations does not overwhelm the body's antioxidant defenses; it stimulates them. This is mechanistically distinct from pathological oxidative stress, where antioxidant capacity is overwhelmed, and from therapeutic high-dose oxidative interventions like IV Vitamin C, which operate by a different mechanism.
When ozone contacts biological fluids — specifically blood plasma and erythrocyte membranes — it reacts with fatty acids to produce lipid ozonization products (LOPs), primarily including hydrogen peroxide (H₂O₂), lipid hydroperoxides, and aldehydes. These LOPs act as biological signal transducers rather than as simple toxic byproducts. They distribute systemically and trigger a cascade of intracellular signaling events that constitute the therapeutic mechanism of MAH.
The primary downstream signaling pathway activated by ozone-generated LOPs is the Nrf2/Keap1/ARE system — the master regulator of cellular antioxidant response. Nrf2 activation drives upregulation of a broad battery of antioxidant and cytoprotective enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase, and heme oxygenase-1 (HO-1). The net effect is a systemically primed antioxidant defense — meaning normal tissues become more resilient to oxidative damage from cancer, chemotherapy, and radiation.
Simultaneously, ozone activates the NF-κB pathway in a dose-dependent, biphasic manner. At therapeutic concentrations, this drives an initial pro-inflammatory cytokine response (TNF-α, IL-6) followed by a rapid anti-inflammatory shift — a cytokine regulation pattern that supports immune activation without chronic inflammation. The Nrf2/NF-κB cross-talk is the molecular basis for ozone's dual immunostimulatory and anti-inflammatory effects.
Cancer cells are paradoxically vulnerable to the oxidative challenge that ozone generates — for the same reason that makes IV Vitamin C selectively toxic to tumors. Cancer cells typically operate with elevated baseline ROS levels (a consequence of their metabolic dysregulation and rapid proliferation) and, critically, have impaired or downregulated antioxidant enzyme systems — particularly catalase and SOD — that make them unable to mount the same Nrf2-mediated adaptive response that protects normal cells.
When ozone-generated LOPs encounter cancer cells with impaired antioxidant defenses, the oxidative load cannot be neutralized — triggering apoptosis via DNA strand breaks, mitochondrial disruption, and caspase activation. Normal cells, with intact Nrf2 response, upregulate their antioxidant enzymes and are protected. This selectivity — high oxidative vulnerability in cancer cells, adaptive resilience in normal cells — is the theoretical basis for ozone's direct anti-tumor potential and mirrors the established selectivity mechanism of pharmacologic ascorbate.
Beyond direct cytotoxicity, ozone exerts broad immunomodulatory effects:
Cytokine modulation — upregulates pro-inflammatory cytokines (IFN-γ, IL-2, TNF-α) relevant to anti-tumor immunity, followed by anti-inflammatory resolution cytokines — net effect is immune activation without chronic inflammatory burden
NK cell activation — stimulates natural killer cell activity — directly relevant to tumor cell surveillance
T-cell regulation — regulatory T lymphocyte modulation; normalizes immune dysregulation common in cancer patients
Erythrocyte oxygenation — MAH increases erythrocyte oxygen-carrying capacity and deformability, improving microcirculation and tissue oxygen delivery — synergistic with HBOT
Mitohormesis — via the AMPK/FOXO/mTOR/Sirt1 pathway, ozone-generated LOPs trigger mitochondrial stress responses that improve metabolic efficiency and cellular resilience
Like HBOT, ozone therapy improves tissue oxygenation through multiple mechanisms: increased erythrocyte deformability (improving microvascular flow to poorly perfused tumor regions), improved oxygen release from hemoglobin (via 2,3-DPG upregulation), and enhanced mitochondrial oxygen utilization. This oxygenation effect synergizes with HBOT's direct hyperbaric mechanism and together they constitute a dual-modality hypoxia reversal approach within the SEED protocol.
The hormesis principle, LOPs as signal transducers, and Nrf2/NF-κB pathway activation are well-established and peer-reviewed at the molecular level. The selective cytotoxicity mechanism — exploiting cancer cells' impaired antioxidant defenses — is mechanistically sound and supported by in vitro data, though human clinical evidence specifically attributing anti-tumor activity to this mechanism is limited. Immune modulation and oxygenation effects have both preclinical and clinical support. The honest mechanistic summary: ozone's biological effects are real, multi-target, and well-characterized — but the clinical translation to measurable anti-tumor outcomes remains the field's primary challenge.
Of the six SEED core therapies, ozone therapy has the most significant gap between its mechanistic rationale and its clinical evidence base for direct anti-tumor activity. The preclinical data is compelling. The supportive care clinical evidence is meaningful and consistent. But as of 2025, the body of well-designed, adequately powered clinical trials specifically demonstrating ozone's anti-tumor effect in human cancer patients lags behind IV Vitamin C, mistletoe, and HBOT.
This does not undermine ozone's inclusion in SEED — but it requires intellectual honesty. Ozone earns its place as a daily systemic preconditioning and supportive care therapy with strong mechanistic rationale and growing clinical evidence. It does not earn its place as a proven direct anti-tumor treatment. The distinction matters for patient counseling, for how we describe the therapy, and for how we prioritize future outcomes tracking.
The same A–D evidence grade framework used throughout the SEED Evidence Series is applied here.
| Grade | Level | Description |
|---|---|---|
| A | Strong | Multiple RCTs or meta-analyses with consistent results |
| B | Moderate | Limited RCTs, prospective cohorts, or phase II trials with positive signal |
| C | Emerging | Phase I trials, uncontrolled studies, strong preclinical data; promising but not definitive |
| D | Limited | Case reports, mechanistic rationale only, or conflicting results |
| Study | Key Finding | Grade |
|---|---|---|
| Clavo et al. — Controlled Study (2023) Int J Environmental Research Cancer Survivors — Chemo & Radiation Toxicity | Ozone treatment significantly improved health-related QOL and reduced toxicity from prior radiotherapy and chemotherapy in symptomatic cancer survivors. Effects observed on chronic pain, peripheral neuropathy, fatigue, and functional capacity. Among the most rigorous ozone oncology clinical studies published to date. | B |
| OzoParQT — Randomized Triple-Blind Trial (2025, registered) CIPN — Chemotherapy-Induced Peripheral Neuropathy NCT06706544 | Registered RCT evaluating effectiveness and cost-effectiveness of ozone therapy for paraesthesia (numbness, tingling) from CIPN. Triple-blind design; outcome assessor blinded. EMA and AEMPS approved. Results pending — the most rigorous prospective trial of ozone in oncology to date. | B |
| Tirelli et al. — Clinical Report (2018) 50 Cancer Patients with Fatigue Oxygen-Ozone Therapy as Palliative Support | 73% of cancer patients treated with MAH ozone therapy during active treatment or in a palliative setting achieved meaningful reduction in fatigue without major side effects. Short report; no control group. One of the most-cited ozone oncology supportive care studies. | C |
| Kontorshchikova et al. — Clinical Trial (2001) 32 Breast Cancer Patients Ozone + Chemotherapy | Patients receiving ozone therapy alongside chemotherapy showed improved QOL, enhanced immune function, and reduced cytostatic toxicity. Improvements in blood oxygen tension, blood flow normalization, and lymphocyte recovery. Small sample, limited design; historically significant as an early clinical trial. | C |
| Clavo et al. — Case Series (2015) 12 Prostate Cancer Patients Radiation-Induced Rectal Bleeding | Patients with refractory radiation proctitis (83% Grade 3–4 toxicity) treated with ozone rectal insufflation and ozonized oil. Median follow-up 104 months. Demonstrated long-term resolution of severe radiation-induced rectal bleeding unresponsive to conventional treatment. Supports ozone for radiation injury management. | C |
| Baeza-Noci et al. — Systematic Review (2021) Int J Molecular Sciences Ozone as Potential Chemotherapy | PRISMA-compliant systematic review of preclinical ozone direct anti-tumor studies. Identified strong in vitro and in vivo evidence of direct cytotoxic effects in cancer cells via intracellular ROS increase. Concludes translation to clinical practice is still limited. Honest acknowledgment: 60 years of preclinical positive data, limited clinical RCT evidence. | C |
| Li & Pu — Integrative Literature Review (2024) Integr Cancer Ther Ozone and Breast Cancer | Systematic review covering preclinical and clinical ozone studies in breast cancer. Documents ozone enhancement of doxorubicin's anti-proliferative effects (MCF7, BT-474 cell lines). Clinical studies show QOL improvement, reduced chemo side effects, improved blood oxygenation, immune restoration. Highlights lack of later-stage clinical trials as key gap. | C |
| Scoping Review — Pain, Fatigue, Anxiety, Depression (2025) 16 Studies in Cancer Patients | Medical ozone reduces cancer-related pain, fatigue, anxiety, and depression across 16 studies. All studies reported significant improvement in majority of patients; none reported significant side effects at therapeutic doses. Supports ozone as a meaningful supportive care intervention across symptom domains. | B |
Strongly supported: Reduction of chemotherapy and radiation-induced side effects. Multiple clinical studies consistently show meaningful improvements in fatigue, peripheral neuropathy, pain, and QOL in patients exposed to conventional cancer treatment toxicity. This is ozone's most reliable clinical contribution in oncology.
Strongly supported: Safety at therapeutic concentrations. Normal tissue does not sustain meaningful damage from ozone at 30–45 μg/mL via MAH because Nrf2-mediated antioxidant upregulation protects it. This selectivity is well-established.
Moderately supported: Radiation injury management. Case series and clinical reports, including long-term follow-up data from the Clavo group, show meaningful benefit for radiation proctitis, cystitis, and soft tissue injury.
Emerging: Direct anti-tumor activity in humans. Preclinical evidence for selective cytotoxicity in cancer cells is strong. Clinical RCT data demonstrating tumor response is not yet available. The OzoParQT trial (registered 2025) will provide the most rigorous data to date.
Emerging: Chemotherapy sensitization / synergy. Preclinical evidence that ozone enhances doxorubicin's effects in breast cancer cell lines is promising. Clinical data is currently limited to early-phase studies and case series.
Not yet established: Survival benefit. No adequately powered RCT has demonstrated an ozone-associated survival advantage in cancer patients. This is a research gap, not evidence of harm.
The honest summary: Ozone belongs in SEED as a systemic preconditioning, supportive care, and immune modulation therapy — not as a proven anti-tumor agent. The mechanistic case for anti-tumor activity is strong. The clinical case is developing. We use it daily because it reliably improves the biological terrain and the patient's treatment tolerance, while the evidence for more direct effects continues to build.
In the SEED 1-week intensive, ozone therapy (MAH) is administered daily — Monday through Friday — alongside HBOT and repurposed drugs. Its daily frequency reflects its role as a systemic terrain conditioner rather than an acute therapeutic intervention. Each MAH session triggers the hormetic Nrf2 response, primes immune cells, improves erythrocyte oxygenation, and generates the circulating LOPs that modulate cellular behavior throughout the day.
Over five consecutive daily sessions, this preconditioning effect accumulates: by Day 3–4, patients are typically exhibiting the full systemic Nrf2-mediated antioxidant upregulation, normalized cytokine profiles, and improved microcirculation that define the therapeutic response. This is why daily frequency matters — a single session generates a signal; five consecutive sessions generate a sustained state change.
Method — major autohemotherapy (MAH) — closed sterile system, 50–200 mL blood withdrawn, ozonated, and reinfused
Ozone concentration — 30–45 μg/mL therapeutic range; total ozone dose per session calculated based on volume and concentration
Frequency in SEED — daily — Monday through Friday during the 1-week intensive
Duration per session — approximately 30–45 minutes including setup, treatment, and reinfusion
Ozone's value in SEED is amplified by its interactions with the other five core therapies:
With HBOT — both improve tissue oxygenation through complementary mechanisms — HBOT via dissolved plasma oxygen, ozone via erythrocyte deformability and 2,3-DPG upregulation; together they constitute a dual-modality hypoxia reversal approach
With IV Vitamin C — both exploit cancer cells' impaired antioxidant defenses; ozone's Nrf2 activation in normal cells provides a degree of antioxidant priming that may protect normal tissue on IVC days; scheduling MAH on non-IVC days avoids potential interaction between the two oxidative mechanisms
With hyperthermia — ozone-improved microcirculation enhances delivery of heat to tumor tissue; hyperthermia-induced heat shock proteins may sensitize tumor cells to ozone-generated ROS
With mistletoe — both activate NK cells and modulate cytokine profiles; delivered on separate days within the SEED schedule, their immune activation effects may be additive
With repurposed drugs — improved microcirculation and reduced tumor hypoxia from ozone and HBOT together enhance drug delivery to tumor tissue
MAH ozone is administered daily — on the same days as HBOT and repurposed drugs (Monday through Friday). It is not scheduled on the same day as IV Vitamin C to avoid stacking two competing oxidative mechanisms simultaneously, though the clinical significance of this interaction remains an area of ongoing investigation. The daily MAH sessions create the systemic preconditioning environment in which the alternating IVC and mistletoe/hyperthermia days operate.
Ozone addresses the cancer terrain at multiple levels simultaneously: the immune microenvironment (NK activation, cytokine normalization), the metabolic environment (Nrf2-mediated antioxidant priming, mitohormesis), and the vascular/oxygenation environment (improved erythrocyte function, microcirculation normalization). In the SEED framework, it is the broadest-acting terrain modifier — not the most powerful at any single mechanism, but the most comprehensive in the range of terrain factors it addresses each session. This is why daily administration makes sense: every day in the SEED intensive is a day in which the full terrain needs to be prepared for the day's primary therapeutic interventions.
Ozone therapy has a well-established safety profile at therapeutic concentrations via MAH. The critical safety principle is dose precision: therapeutic benefit and safety both depend on administering ozone within the defined concentration range (10–80 μg/mL; optimal 30–45 μg/mL). Outside this range, adverse effects increase meaningfully.
| Consideration | Clinical Detail | Management |
|---|---|---|
| Ozone Inhalation (ABSOLUTE) | Ozone gas is toxic to lung tissue at any concentration. Direct inhalation causes acute respiratory inflammation and is not a therapeutic route under any circumstances. This applies to accidental exposure during MAH procedures. | Closed, sterile MAH systems with one-way valves prevent gas escape. Room ventilation required. Ozone generator must not be operated in enclosed spaces without proper exhaust. Never administer ozone via inhalation. |
| G6PD Deficiency | G6PD-deficient patients have impaired antioxidant capacity in erythrocytes; ozone-generated oxidative stress via MAH can trigger hemolytic anemia — the same risk as with high-dose IV Vitamin C. | Screen for G6PD deficiency before initiating MAH. Absolute contraindication in quantitatively confirmed G6PD deficiency. |
| Pregnancy | Ozone's systemic oxidative and immunostimulatory effects are contraindicated during pregnancy. | Absolute contraindication in pregnancy. |
| Uncontrolled Hyperthyroidism | Ozone's metabolic stimulation may exacerbate thyroid hyperactivity. | Screen TSH/free T4. Treat hyperthyroidism before initiating ozone therapy. |
| Active Severe Bleeding / Hemorrhagic Conditions | Ozone at high concentrations has anticoagulant properties; in patients with active hemorrhage or thrombocytopenia, MAH carries hemorrhagic risk. | Assess platelet count and coagulation status. Defer MAH in patients with active severe bleeding or significant thrombocytopenia (platelet count <50,000 in most protocols). |
| Cardiovascular Instability | MAH involves a modest hemodynamic challenge during reinfusion. Patients with severe cardiac compromise (decompensated CHF, severe arrhythmia, recent MI) require cardiac clearance. | Cardiology clearance for patients with significant cardiac history. Monitor during reinfusion phase. |
| Overdose / Excessive Concentration | Ozone above 80 μg/mL or excessive total ozone dose produces meaningful cytotoxic and inflammatory effects in normal tissue. This is an iatrogenic risk from imprecise dosing, not an inherent property of therapeutic ozone. | Calibrated ozone generator with concentration monitoring required. Dose protocol must specify both concentration (μg/mL) and volume to calculate total ozone dose. Clinician training and generator quality are non-negotiable safety requirements. |
| Common Mild Side Effects (MAH) | Mild fatigue, warmth during reinfusion, transient lightheadedness, and occasional nausea in the hours following MAH. Generally mild and transient. | Patient hydration before and after procedure. Slow reinfusion rate. Monitor during and immediately after session. |
Ozone earns its place as a daily core therapy in the SEED Program for the following reasons — stated with appropriate honesty about the current state of its evidence:
Broadest terrain coverage per session — in a single MAH treatment, ozone simultaneously addresses immune activation, antioxidant priming, oxygenation, microcirculation, cytokine normalization, and mitochondrial function — no other single SEED therapy addresses as many terrain dimensions simultaneously
Synergistic amplifier for all other SEED therapies — ozone's effects on oxygenation, microcirculation, and antioxidant priming create conditions that improve the efficacy of IV Vitamin C, HBOT, mistletoe, hyperthermia, and repurposed drugs
Strongest supportive care evidence — reliable reduction of chemotherapy- and radiation-induced side effects — fatigue, peripheral neuropathy, pain — is among the most consistent findings in the ozone oncology literature
Selective toxicity mechanism — the Nrf2-mediated selectivity that protects normal tissue while potentially sensitizing cancer cells is mechanistically robust, even while the clinical evidence for direct anti-tumor activity is still developing
Safety at therapeutic doses is well-established — dose-dependent safety with a defined therapeutic window; normal tissue is protected by the very mechanism that makes cancer cells vulnerable
Daily feasibility — MAH is a 30–45 minute procedure that integrates readily into the SEED daily schedule alongside HBOT and other therapies
Baeza-Noci J, Pablos-Herreros A. Systemic review: ozone: a potential new chemotherapy. Int J Mol Sci. 2021;22(21):11796.
Clavo B, Cánovas-Molina A, Ramallo-Fariña Y, et al. Effects of ozone treatment on health-related quality of life and toxicity induced by radiotherapy and chemotherapy in symptomatic cancer survivors. Int J Environ Res Public Health. 2023;20(2):1479.
Clavo B, Rodríguez-Abreu D, Galván S, et al. Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: a preliminary report. Front Physiol. 2022;13:935269.
Clavo B, Cánovas-Molina A, Ramallo-Fariña Y, et al. Effectiveness and cost-effectiveness of ozone treatment in patients with paraesthesia secondary to CIPN: randomized triple-blind clinical trial (OzoParQT). BMC Cancer. 2025. NCT06706544.
Clavo B, Navarro M, Zamora P, et al. Ozone therapy in the management of persistent radiation-induced rectal bleeding in prostate cancer patients. Evid Based Complement Alternat Med. 2015;2015:480369.
Li Y, Pu R. Ozone therapy for breast cancer: an integrative literature review. Integr Cancer Ther. 2024;23:15347354241226667.
Tirelli U, Cirrito C, Pavanello M, et al. Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue: a short report. Eur Rev Med Pharmacol Sci. 2018;22(24):8030–8033.
Molina AFR, et al. High-dose ozone therapy in oncology patients: efficacy, mechanisms, and therapeutic potential. Genesis Pub. 2024.
Kontorshchikova CN, et al. Ozone therapy in complex treatment of breast cancer patients. Eur J Anaesthesiol. 2001.
Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Med Gas Res. 2011;1:29.
Pecorelli A, Bocci V, Acquaviva A, et al. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol. 2013;267(1):30–40.
Scoping Review: Medical ozone treatment for pain, fatigue, anxiety, and depression in cancer patients. 16 included studies. Front Oncol. 2025.
This white paper is prepared for clinical and provider education purposes as part of the Root Causes SEED Program Evidence Series. It summarizes published research and does not constitute medical advice. All clinical decisions should be individualized by a qualified provider. Evidence grades reflect the authors' assessment of the published literature at time of writing and will be updated as new research emerges.